EMA panel recommends approval of AstraZeneca therapy to prevent COVID (updated)
hapabapa/iStock Editorial via Getty Images


An advisory panel of the European Medicines Agency has recommended approval of Evusheld, an antibody therapy from AstraZeneca (AZN +0.5%) for prevention of COVID-19.
Evusheld is comprised of tixagevimab co-packaged with cilgavimab. It is intended for individuals whose immune system can't handle a COVID vaccine.

The agency's Committee for Medicinal Products for Human Use ("CHMP") made the recommendation on Thursday.
The European Commission will still need to grant final authorization, though that is expected to happen quickly.
Evusheld is already authorized in the U.S. and UK.
Read why Seeking Alpha contributor Nathan Aisenstadt says AstraZeneca (AZN +0.5%) is a hold.